Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
The present disclosure provides for treating neurodegenerative diseases and lysosomal storage disorders comprising administering leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof. The disclosure further provides for leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof, for example, in an elderly subject, to improve cognitive function, mobility, or cognitive function and mobility.
1 . A method for treating a lysosomal storage disorder (LSD) comprising:
directly delivering leucine, or a pharmaceutically acceptable salt thereof, to the central nervous system of a subject having LSD or one or more symptoms associated with a LSD;
wherein the leucine, or pharmaceutically acceptable salt thereof, is delivered in a therapeutically effective amount to treat the LSD or the one or more symptoms associated with the LSD;
wherein the direct delivery is by an administration chosen from intrathecal administration and intracranial administration;
wherein the LSD is chosen from Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Niemann-Pick type C disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria; and
wherein the leucine is not acetyl-leucine and wherein the therapeutically effective amount of leucine is administered to the subject for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years.
2 . The method of claim 1 , wherein the LSD is chosen from Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann Pick type A disease, Niemann-Pick type C disease, mucolipidosis II mucolipidosis III, MPS MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria.
3 . The method of claim 1 , wherein the subject is asymptomatic.
4 . The method of claim 3 , wherein the subject has been found to have a genetic and/or biochemical marker of the LSD.
5 . The method of claim 1 , wherein the method comprises initiating delivery of a therapeutically effective amount of leucine to the subject in need thereof when the subject is asymptomatic.
6 . The method of claim 5 , wherein the initial delivery occurs after the subject has been found to have a genetic and/or biochemical marker of the LSD.
7 . The method of claim 1 , wherein the leucine is DL-leucine.
8 . The method of claim 1 , wherein the leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.
9 . The method of claim 8 , wherein the single enantiomeric form is the L-enantiomer.
10 . The method of claim 1 , wherein the direct delivery is by intrathecal administration.
11 . The method of claim 1 , wherein treating the LSD is delaying the progression of LSD.
12 . The method of claim 1 , wherein treating the LSD is reversing progression of the LSD.
13 . The method of claim 1 , wherein treating the LSD is improving a biochemical marker of the LSD.